Diabetes Research Institute
Miami, Florida, 33136, United States
NCT Number: NCT03063515
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Miami, Florida, 33136, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single oral dose of 60 mg pyridostigmine tablet
Other names: Mestinon
Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes
Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion
Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes
Glucose positive incremental area under the curve
University of Miami
Other
Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings
Acronym: AchE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07728162
Diabetes Mellitus, Disease Attributes
Bolu, Turkey (Türkiye)
View Trial Details